Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valacyclovir + Celecoxib (IMC-2) for Long COVID
NCT06316843Phase 2Completed
- Sponsor
- Bateman Horne Center
- Start
- Oct 2023
- Primary completion
- Oct 2024
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of valaciclovir, celecoxib in post-acute sequelae of SARS-CoV-2 infection (PASC), sponsored by Bateman Horne Center. Started Oct 2023; status: completed.
02
Drugs
valaciclovircelecoxib
03
Conditions
post-acute sequelae of SARS-CoV-2 infection (PASC)
Beyond the preview
Go deeper on NCT06316843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06316843.